The type classification of the Digital Inhalers market distinguishes four principal product families: dose‑counter inhalers, smart‑connected inhalers, breath‑actuated inhalers, and multi‑dose inhalers. Dose‑counter devices, which integrate a mechanical counter to display remaining actuations, generate roughly 30 % of market revenue because they represent the lowest‑cost entry point for digital compliance monitoring. Smart‑connected inhalers, equipped with Bluetooth or Wi‑Fi modules that relay real‑time usage to mobile applications, dominate the high‑value segment, contributing about 45 % of sales; their premium pricing reflects added analytics and telehealth integration capabilities. Breath‑actuated inhalers, which trigger aerosol release only upon sufficient inspiratory flow, account for approximately 15 % of the market, driven by clinical preference in pediatric and severe‑disease cohorts where coordination is limited. Multi‑dose inhalers, capable of delivering variable drug quantities from a single cartridge, hold the remaining 10 % share, primarily in markets where combination therapies are standard. By quantifying each type’s share, analysts can assess technology adoption trends and forecast revenue trajectories within the Digital Inhalers segmentation framework.
